Affordable Access

Publisher Website

Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate.

Authors
Type
Published Article
Journal
Epilepsia
Publication Date
Volume
52
Issue
10
Pages
1877–1883
Identifiers
DOI: 10.1111/j.1528-1167.2011.03183.x
PMID: 21770925
Source
Medline

Abstract

Although bioequivalent to Topamax in extent of absorption, USL255 had a slower absorption rate as reflected in its lower C(max) and longer t(max), larger POT and longer t(1/2,eff), and similar R(ac) values to that of Topamax (q12 h). This relative flat plasma profile allows for once-daily dosing with diminished fluctuations in TPM plasma levels. In addition, neither USL255's peak nor extent of plasma exposure of TPM was affected by food.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments